Arrowhead Pharma (ARWR) Stock Surges 481% as Analysts Bet Big on Plozasiran

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2026-04-21 18:09:02

BTCCSquare news:

Arrowhead Pharmaceuticals has become a Wall Street darling, its shares soaring 481% over the past year. The rally accelerated this week after Morgan Stanley upgraded the stock to Overweight with a $100 price target—a 39% upside from current levels.

The biotech's fortunes hinge on plozasiran, its experimental treatment for severe hypertriglyceridemia. Phase 3 data expected in Q3 2026 could unlock what analyst Michael Ulz calls a "multibillion-dollar opportunity." Morgan Stanley now models peak sales at $3.2 billion, nearly double prior estimates.

Bank of America echoed the optimism, projecting a $3 billion market for the drug. The bullish calls come as ARWR shares gained another 3.9% Tuesday, extending their year-to-date rise to 8.2%.

By:

Log in to Reply

Deribit Exchange Braces for $8 Billion Bitcoin Options Expiry Amid Macroeconomic Crosscurrents

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.